We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, DEA TO PEN MORE EXPLICIT LABELING RULES FOR SCHEDULE II DRUGS
FDA, DEA TO PEN MORE EXPLICIT LABELING RULES FOR SCHEDULE II DRUGS
March 1, 2004
The FDA and the Drug Enforcement Administration (DEA) are developing new, more explicit labeling guidelines for manufacturers of controlled substances like Purdue Pharma’s OxyContin and Abbott Laboratories’ Vicodin in an effort to curb widespread abuse of the prescription painkillers.